VXA-CoV2-3.3

VXA-CoV2-3.3 · Vaxart, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VXA-CoV2-3.3, covering 2025-10-22 to 2025-10-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection [Phase 2]

See pricing